Bridget Martell, M.D., M.A.
Biopharma Executive and Entrepreneur
Image
| Dr. Martell is a seasoned biopharmaceutical corporate executive with high-impact, results-oriented breadth and depth with a demonstrated track record in financing, building, and leading highly successful companies. An inspiring global corporate leader that brings deep scientific and commercial acumen to her leadership roles and has held operational roles in “bed to bedside” drug development through drug product approvals and commercialization across a range of therapeutic areas and disease indications. Skilled in identifying and executing on innovative approaches in drug development, applying adaptive clinical research methodologies to complex programs, and leveraging advantageous regulatory pathways whilst maintaining close collaborations with investigators and consortiums. With this extensive scientific acumen, she has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilars Ogiviri®, as well as secondary indications for Pradaxa® and Sutent®. Dr. Martell has held leadership and C-suite executive roles at companies including Artizan Biosciences where she leads a precision medicine drug development platform company focusing on inflammatory disease and the microbiome, Kura Oncology, where she led the Menin Inhibitor Program through a $500+M financing, and at Juniper Pharmaceuticals, where she led the development program for a Bob Langer-created drug/device technology that was out-licensed for $131M. |